Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer

Korkola, James E.; Collisson, Eric A.; Heiser, Laura; Oates, Chris; Bayani, Nora; Itani, Sleiman; Esch, Amanda; Thompson, Wallace; Griffith, Obi L.; Wang, Nicholas J.; Kuo, Wen -Lin; Cooper, Brian; Billig, Jessica; Ziyad, Safiyyah; Hung, Jenny L.; Jakkula, Lakshmi; Feiler, Heidi; Lu, Yiling; Mills, Gordon B.; Spellman, Paul T.; Tomlin, Claire; Mukherjee, Sach; Gray, Joe W.; Wong, Kwong -Kwok

doi:10.1371/journal.pone.0133219

Title: Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer

Journal Article · Thu Jul 16 00:00:00 EDT 2015 · PLoS ONE

DOI:https://doi.org/10.1371/journal.pone.0133219· OSTI ID:1212476

Korkola, James E. ^[1]; Collisson, Eric A. ^[2]; Heiser, Laura ^[1]; Oates, Chris ^[3]; Bayani, Nora ^[4]; Itani, Sleiman ^[5]; Esch, Amanda ^[1]; Thompson, Wallace ^[1]; Griffith, Obi L. ^[4]; Wang, Nicholas J. ^[1]; Kuo, Wen -Lin ^[4]; Cooper, Brian ^[4]; Billig, Jessica ^[4]; Ziyad, Safiyyah ^[4]; Hung, Jenny L. ^[4]; Jakkula, Lakshmi ^[4]; Feiler, Heidi ^[6]; Lu, Yiling ^[7]; Mills, Gordon B. ^[7]; Spellman, Paul T. ^[1] more »

Oregon Health Sciences Univ., Portland, OR (United States)
Univ. of California San Francisco, San Francisco, CA (United States)
Netherlands Cancer Institute, Amsterdam (The Netherlands); Univ. of Warwick, Coventry (United Kingdom)
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Univ. of California, Berkeley, CA (United States)
Oregon Health Sciences Univ., Portland, OR (United States); Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
MD Anderson Cancer Center, Houston, TX (United States)
Netherlands Cancer Institute, Amsterdam (The Netherlands); German Center for Neurodegenerative Diseases, Bonn (Germany)
Univ. of Texas, Houston, TX (United States). MD Anderson Cancer Center.

We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2⁺ breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors (AKT_i) GSK690693 and GSK2141795 in a panel of 22 HER2⁺ breast cancer cell lines carrying wild type or mutant PIK3CA. We observed that combinations of lapatinib plus AKT_i were synergistic in HER2/PIK3CA^mut cell lines but not in HER2⁺/PIK3CA^wt cell lines. We measured changes in phospho-protein levels in 15 cell lines after treatment with lapatinib, AKT_i or lapatinib + AKT_i to shed light on the underlying signaling dynamics. This revealed that p-S6RP levels were less well attenuated by lapatinib in HER2⁺/PIK3CA^mut cells compared to HER2⁺/PIK3CA^wt cells and that lapatinib + AKT_i reduced p-S6RP levels to those achieved in HER2⁺/PIK3CA^wt cells with lapatinib alone. We also found that that compensatory up-regulation of p-HER3 and p-HER2 is blunted in PIK3CA^mut cells following lapatinib + AKT_i treatment. Responses of HER2⁺ SKBR3 cells transfected with lentiviruses carrying control or PIK3CA^mut sequences were similar to those observed in HER2⁺/PIK3CA^mut cell lines but not in HER2⁺/PIK3CA^wt cell lines. We used a nonlinear ordinary differential equation model to support the idea that PIK3CA mutations act as downstream activators of AKT that blunt lapatinib inhibition of downstream AKT signaling and that the effects of PIK3CA mutations can be countered by combining lapatinib with an AKT_i. This combination does not confer substantial benefit beyond lapatinib in HER2⁺/PIK3CA^wt cells.

View Accepted Manuscript (DOE)

Cite

Export

Save

Research Organization:: Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)

Sponsoring Organization:: USDOE; National Cancer Institute (NCI)

Grant/Contract Number:: AC02-05CH11231

OSTI ID:: 1212476

Journal Information:: PLoS ONE, Vol. 10, Issue 7; ISSN 1932-6203

Publisher:: Public Library of ScienceCopyright Statement

Country of Publication:: United States

Language:: English

Citation Metrics:

Cited by: 16 works

Citation information provided by
Web of Science

References (42)

Understanding resistance to combination chemotherapy Pritchard, Justin R.; Lauffenburger, Douglas A.; Hemann, Michael T. Drug Resistance Updates, Vol. 15, Issue 5-6 https://doi.org/10.1016/j.drup.2012.10.003	journal	October 2012
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib Wang, Leiping; Zhang, Qunling; Zhang, Jian BMC Cancer, Vol. 11, Issue 1 https://doi.org/10.1186/1471-2407-11-248	journal	June 2011
Combinatorial drug therapy for cancer in the post-genomic era Al-Lazikani, Bissan; Banerji, Udai; Workman, Paul Nature Biotechnology, Vol. 30, Issue 7 https://doi.org/10.1038/nbt.2284	journal	July 2012
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells Tibes, R.; Qiu, Y.; Lu, Y. Molecular Cancer Therapeutics, Vol. 5, Issue 10 https://doi.org/10.1158/1535-7163.mct-06-0334	journal	October 2006
Cluster analysis and display of genome-wide expression patterns Eisen, M. B.; Spellman, P. T.; Brown, P. O. Proceedings of the National Academy of Sciences, Vol. 95, Issue 25 https://doi.org/10.1073/pnas.95.25.14863	journal	December 1998
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer Berns, Katrien; Horlings, Hugo M.; Hennessy, Bryan T. Cancer Cell, Vol. 12, Issue 4 https://doi.org/10.1016/j.ccr.2007.08.030	journal	October 2007
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Holbro, T.; Beerli, R. R.; Maurer, F. Proceedings of the National Academy of Sciences, Vol. 100, Issue 15 https://doi.org/10.1073/pnas.1537685100	journal	July 2003
Rare cancer-specific mutations in PIK3CA show gain of function Gymnopoulos, M.; Elsliger, M. -A.; Vogt, P. K. Proceedings of the National Academy of Sciences, Vol. 104, Issue 13 https://doi.org/10.1073/pnas.0701005104	journal	March 2007
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Esteva, Francisco J.; Guo, Hua; Zhang, Siyuan The American Journal of Pathology, Vol. 177, Issue 4 https://doi.org/10.2353/ajpath.2010.090885	journal	October 2010
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Sergina, Natalia V.; Rausch, Megan; Wang, Donghui Nature, Vol. 445, Issue 7126 https://doi.org/10.1038/nature05474	journal	January 2007
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 Chakrabarty, A.; Rexer, B. N.; Wang, S. E. Oncogene, Vol. 29, Issue 37 https://doi.org/10.1038/onc.2010.257	journal	June 2010
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Neve, Richard M.; Chin, Koei; Fridlyand, Jane Cancer Cell, Vol. 10, Issue 6 https://doi.org/10.1016/j.ccr.2006.10.008	journal	December 2006
Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy Lee, J. J.; Kong, M.; Ayers, G. D. Journal of Biopharmaceutical Statistics, Vol. 17, Issue 3 https://doi.org/10.1080/10543400701199593	journal	May 2007
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML Winter, Georg E.; Rix, Uwe; Carlson, Scott M. Nature Chemical Biology, Vol. 8, Issue 11 https://doi.org/10.1038/nchembio.1085	journal	September 2012
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047 Kuo, Wen-Lin; Das, Debopriya; Ziyad, Safiyyah BMC Medicine, Vol. 7, Issue 1 https://doi.org/10.1186/1741-7015-7-77	journal	December 2009
Bioconductor: open software development for computational biology and bioinformatics Gentleman, Robert C.; Carey, Vincent J.; Bates, Douglas M. Genome Biology, Vol. 5, Issue 10, p. R80 https://doi.org/10.1186/gb-2004-5-10-r80	journal	September 2004
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer Razis, E.; Bobos, M.; Kotoula, V. Breast Cancer Research and Treatment, Vol. 128, Issue 2 https://doi.org/10.1007/s10549-011-1572-5	journal	May 2011
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity Chandarlapaty, Sarat; Sawai, Ayana; Scaltriti, Maurizio Cancer Cell, Vol. 19, Issue 1 https://doi.org/10.1016/j.ccr.2010.10.031	journal	January 2011
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity Scaltriti, M.; Verma, C.; Guzman, M. Oncogene, Vol. 28, Issue 6 https://doi.org/10.1038/onc.2008.432	journal	December 2008
A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy Lee-Hoeflich, S. T.; Crocker, L.; Yao, E. Cancer Research, Vol. 68, Issue 14 https://doi.org/10.1158/0008-5472.can-08-0380	journal	July 2008
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer Blackwell, Kimberly L.; Burstein, Harold J.; Storniolo, Anna Maria Journal of Clinical Oncology, Vol. 28, Issue 7 https://doi.org/10.1200/JCO.2008.21.4437	journal	March 2010
Unraveling the Biologic and Clinical Complexities of HER2 Park, John W.; Neve, Richard M.; Szollosi, Janos Clinical Breast Cancer, Vol. 8, Issue 5 https://doi.org/10.3816/CBC.2008.n.047	journal	October 2008
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven New England Journal of Medicine, Vol. 344, Issue 11 https://doi.org/10.1056/NEJM200103153441101	journal	March 2001
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Geyer, Charles E.; Forster, John; Lindquist, Deborah New England Journal of Medicine, Vol. 355, Issue 26 https://doi.org/10.1056/NEJMoa064320	journal	December 2006
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Piccart-Gebhart, Martine J.; Procter, Marion; Leyland-Jones, Brian New England Journal of Medicine, Vol. 353, Issue 16 https://doi.org/10.1056/NEJMoa052306	journal	October 2005
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer Johnston, Stephen; Pippen, John; Pivot, Xavier Journal of Clinical Oncology, Vol. 27, Issue 33 https://doi.org/10.1200/JCO.2009.23.3734	journal	November 2009
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers Dave, Bhuvanesh; Migliaccio, Ilenia; Gutierrez, M. Carolina Journal of Clinical Oncology, Vol. 29, Issue 2 https://doi.org/10.1200/JCO.2009.27.7814	journal	January 2011
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity Rhodes, N.; Heerding, D. A.; Duckett, D. R. Cancer Research, Vol. 68, Issue 7 https://doi.org/10.1158/0008-5472.CAN-07-5783	journal	April 2008
An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer Stemke-Hale, K.; Gonzalez-Angulo, A. M.; Lluch, A. Cancer Research, Vol. 68, Issue 15 https://doi.org/10.1158/0008-5472.CAN-07-6854	journal	August 2008
Active Site Inhibitors Protect Protein Kinase C from Dephosphorylation and Stabilize Its Mature Form Gould, Christine M.; Antal, Corina E.; Reyes, Gloria Journal of Biological Chemistry, Vol. 286, Issue 33 https://doi.org/10.1074/jbc.M111.272526	journal	June 2011
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition Mirzoeva, O. K.; Das, D.; Heiser, L. M. Cancer Research, Vol. 69, Issue 2 https://doi.org/10.1158/0008-5472.CAN-08-3389	journal	January 2009
SNHG7 is a lncRNA oncogene controlled by Insulin-like Growth Factor signaling through a negative feedback loop to tightly regulate proliferation Boone, David N.; Warburton, Andrew; Som, Sreeroopa Scientific Reports, Vol. 10, Issue 1 https://doi.org/10.1038/s41598-020-65109-7	journal	May 2020
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Rubin, Eric J.; Hamel, Mary Beth New England Journal of Medicine, Vol. 356, Issue 14, p. 1487-1487 https://doi.org/10.1056/nejmx070016	journal	April 2007
Comprehensive molecular portraits of human breast tumours Charles, Perou, The University of North Carolina at Chapel Hill University Libraries https://doi.org/10.17615/hyeb-c392	text	January 2012
HER2 Blockade: Is Combination Therapy Better Than Monotherapy? Hirsh, Rebecca L.; Fox, Kevin R. Current Treatment Options in Oncology, Vol. 11, Issue 3-4 https://doi.org/10.1007/s11864-010-0125-1	journal	November 2010
PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance? Park, Ben Ho; Davidson, Nancy E. Cancer Cell, Vol. 12, Issue 4 https://doi.org/10.1016/j.ccr.2007.10.004	journal	October 2007
Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer? Montemurro, Filippo; Aglietta, Massimo Nature Clinical Practice Oncology, Vol. 4, Issue 7 https://doi.org/10.1038/ncponc0849	journal	June 2007
Rational discovery of molecular glue degraders via scalable chemical profiling Mayor-Ruiz, Cristina; Bauer, Sophie; Brand, Matthias Nature Chemical Biology, Vol. 16, Issue 11 https://doi.org/10.1038/s41589-020-0594-x	journal	August 2020
Subtype and pathway specific responses to anticancer compounds in breast cancer Heiser, L. M.; Sadanandam, A.; Kuo, W. -L. Proceedings of the National Academy of Sciences, Vol. 109, Issue 8 https://doi.org/10.1073/pnas.1018854108	journal	October 2011
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver Amin, D. N.; Sergina, N.; Ahuja, D. Science Translational Medicine, Vol. 2, Issue 16 https://doi.org/10.1126/scitranslmed.3000389	journal	January 2010
Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile? Russillo, Michelangelo; Di Benedetto, Anna; Metro, Giulio Journal of Clinical Oncology, Vol. 29, Issue 20 https://doi.org/10.1200/jco.2011.35.1742	journal	July 2011
Bioconductor : open software development for computational biology and bioinformatics C., Gentleman, Robert; J., Carey, Vincent; M., Bates, Douglas BioMed Central https://doi.org/10.21256/zhaw-1907	text	January 2004

Cited By (4)

Delineating feedback activity in the MAPK and AKT pathways using feedback-enabled Inference of Signaling Activity Thijssen, Bram; Jastrzebski, Katarzyna; Beijersbergen, Roderick L. BioRxiv https://doi.org/10.1101/268359	posted_content	February 2018
GRB7 dependent proliferation of basal‐like, HER‐2 positive human breast cancer cell lines is mediated in part by HER‐1 signaling Luoh, Shiuh‐Wen; Wagoner, Wendy; Wang, Xiaoyan Molecular Carcinogenesis, Vol. 58, Issue 5 https://doi.org/10.1002/mc.22963	journal	January 2019
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes Watson, Spencer S.; Dane, Mark; Chin, Koei Cell Systems, Vol. 6, Issue 3 https://doi.org/10.1016/j.cels.2018.02.001	journal	March 2018
Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution Kwon, Sunjong; Chin, Koei; Nederlof, Michel Scientific Reports, Vol. 7, Issue 1 https://doi.org/10.1038/s41598-017-16492-1	journal	November 2017

Similar Records

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

Journal Article · Mon Jul 27 00:00:00 EDT 2009 · Breast Cancer Research Treatment · OSTI ID:1212476

Weigelt, Britta; Lo, Alvin T; Park, Catherine C; +2 more

An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer

Journal Article · Tue May 06 00:00:00 EDT 2008 · Cancer Research · OSTI ID:1212476

Stemke-Hale, Katherine; Gonzalez-Angulo, Ana Maria; Lluch, Ana; +19 more

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

Journal Article · Wed Aug 31 00:00:00 EDT 2011 · Breast Cancer Research · OSTI ID:1212476

Huang, Catherine; Park, Catherine C.; Hilsenbeck, Susan G.; +7 more

Related Subjects

60 APPLIED LIFE SCIENCES
breast cancer
cancer treatment
drug therapy
MAPK signaling cascades
signal inhibition
AKT signaling cascade
confidence intervals
drug interactions

Title: Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer

Citation Formats

References (42)

Cited By (4)

Similar Records

Related Subjects